中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (1): 59-63.doi: 10.35541/cjd.20210947

• 研究报道 • 上一篇    下一篇

【开放获取】 接受生物制剂治疗的银屑病患者COVID-19疫苗接种情况及对原发病影响的单中心横断面研究

杨莹1    郭青1    侯素春1    闵雪1    田佳彬1    乔朱卉1    林佳琳1    王小飞2    乌兰图雅1    张振颖1    李正风1    王彬1    刘晓明1    

  1. 1香港大学深圳医院皮肤科，深圳  518000；2卫健智能（深圳）有限公司，深圳  518000
  • 收稿日期:2021-12-30 修回日期:2022-10-17 发布日期:2023-01-03
  • 通讯作者: 刘晓明 E-mail:liuxm@hku-szh.org
  • 基金资助:
    广东省卫健委高水平医院计划项目（HKUSZH201906001）；香港大学深圳医院高水平医院建设科研培育计划重点项目（HKUSZH201902010）

COVID-19 vaccination status and its impact on psoriatic lesions in patients with psoriasis treated with biologics: a single-center cross-sectional study

Yang Ying1, Guo Qing1, Hou Suchun1, Min Xue1, Tian Jiabin1, Qiao Zhuhui1, Lin Jialin1, Wang Xiaofei2, Wu Lantuya1, Zhang Zhenying1, Li Zhengfeng1, Wang Bin1, Liu Xiaoming1   

  1. 1Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518000, China; 2Medical Health Intelligent （Shenzhen） Co., Ltd., Shenzhen 518000, China
  • Received:2021-12-30 Revised:2022-10-17 Published:2023-01-03
  • Contact: Liu Xiaoming E-mail:liuxm@hku-szh.org
  • Supported by:
    High Level-Hospital Program, Health Commission of Guangdong Province, China（HKUSZH201906001）; High Level-Hospital Program, The University of Hong Kong-Shenzhen Hospital（HKUSZH201902010）

PDF

413

摘要： 【摘要】 目的 了解接受生物制剂治疗的银屑病患者COVID-19疫苗接种和不良反应发生情况及对原发病的影响。方法 在已经构建的生物制剂治疗银屑病患者管理平台中调取香港大学深圳医院2019年5月至2021年6月登记的572例18 ~ 60岁银屑病患者的相关资料，采用电话访问的方式调查疫苗接种情况，由固定人员在固定时间内按照已经制定的问卷获得疫苗接种相关信息。两组间计量资料比较采用t检验，计数资料比较采用卡方检验或Fisher确切概率检验。结果 完成电话访问的524例患者中，疫苗接种率为43.13%（226例）； 生物制剂治疗组接种率（30.79%，105/341）明显低于传统药物治疗组（66.12%，121/183），χ2 = 60.60，P < 0.001； 未接种的主要原因是患者恐惧（49.66%，148/298），其次为医生不推荐（26.51%，79/298）。生物制剂治疗组接种疫苗的患者延长治疗间隔后出现皮损加重的比例（6/14）明显高于规律治疗的患者（4.40%，4/91），Fisher确切概率检验显示两组间差异有统计学意义（P < 0.001）。2例接种COVID-19疫苗后皮损严重加重的患者均是在应用生物制剂治疗时出现过敏反应且皮损尚未完全消退的患者。结论 接受生物制剂治疗的银屑病患者COVID-19疫苗接种率明显偏低，接种疫苗后未见严重不良反应，因接种疫苗而延长治疗间隔有引起皮损加重的风险。

关键词: 银屑病, 生物制剂, 冠状病毒感染, 病毒疫苗, COVID-19, 横断面研究

Abstract: 【Abstract】 Objective To investigate COVID-19 vaccination status and relevant adverse reactions in patients with psoriasis treated with biological agents, and to explore the effect of COVID-19 vaccination on psoriatic lesions. Methods Clinical data were collected from 572 psoriasis patients aged 18 - 60 years, who were registered in the management system of psoriasis patients treated with biological agents in the University of Hong Kong-Shenzhen Hospital from May 2019 to June 2021. The COVID-19 vaccination status was investigated by telephone interviews, and the vaccination-related information was obtained by fixed healthcare workers during a fixed time period according to a predesigned questionnaire. Measurement data were compared between two groups by using t test, and enumeration data were compared by using chi-square test or Fisher′s exact test. Results The COVID-19 vaccination coverage rate was 43.13% （226 cases） among the 524 patients who completed the telephone interview, and was significantly lower in the biological agent treatment group （30.79%, 105/341） than in the traditional drug treatment group （66.12%, 121/183; χ2 = 60.60, P < 0.001）. The main reason for not being vaccinated was patients′ fear of vaccine safety （49.66%, 148/298）, followed by doctors′ not recommending （26.51%, 79/298）. In the biological agent treatment group after vaccination, the exacerbation of psoriatic lesions was more common in patients receiving prolonged-interval treatment （42.86%, 6/14） compared with those receiving regular treatment （4.40%, 4/91; Fisher′s exact test, P < 0.001）. Skin lesions were severely aggravated in two patients after COVID-19 vaccination, who ever experienced allergic reactions and whose skin lesions did not completely subside after the treatment with biological agents. Conclusions The COVID-19 vaccination coverage rate was relatively low in the psoriasis patients treated with biological agents, and no serious adverse reaction was observed after vaccination. Prolonged-interval treatment due to COVID-19 vaccination ran the risk of exacerbation of skin lesions.

Key words: Psoriasis, Biological agents, Coronavirus infections, Viral vaccines, COVID-19, Cross-sectional studies